How I treat hemochromatosis.
暂无分享,去创建一个
[1] D. English,et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer , 2010, Hepatology.
[2] K. Kowdley,et al. The role of iron in the pathophysiology and treatment of chronic hepatitis C. , 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[3] H. Bonkovsky,et al. A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study. , 2009 .
[4] V. Sachdev,et al. Does Oxidative Stress Modulate Left Ventricular Diastolic Function in Asymptomatic Subjects with Hereditary Hemochromatosis? , 2009, Echocardiography.
[5] P. Adams. The Natural History of Untreated HFE-Related Hemochromatosis , 2009, Acta Haematologica.
[6] J. Barton,et al. Hemochromatosis and Vibrio vulnificus Wound Infections , 2009, Journal of clinical gastroenterology.
[7] G. Anderson,et al. Hepcidin regulation in wild-type and Hfe knockout mice in response to alcohol consumption: evidence for an alcohol-induced hypoxic response. , 2009, Alcoholism, clinical and experimental research.
[8] V. Subramaniam,et al. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. , 2009, Biochimica et biophysica acta.
[9] C. Camaschella. BMP6 orchestrates iron metabolism , 2009, Nature Genetics.
[10] D. English,et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. , 2008, Gastroenterology.
[11] P. Adams. Natural history of hemochromatosis: heading down the up escalator? , 2008, Gastroenterology.
[12] J. Pankow,et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. , 2008, Translational research : the journal of laboratory and clinical medicine.
[13] M. Knuiman,et al. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. , 2008, Mayo Clinic proceedings.
[14] J. Barton. Ferritin >1000: grand for hemochromatosis screening? , 2008 .
[15] R. Williamson,et al. Asymptomatic individuals at genetic risk of haemochromatosis take appropriate steps to prevent disease related to iron overload , 2008, Liver international : official journal of the International Association for the Study of the Liver.
[16] V. de Lédinghen,et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. , 2008, Gastroenterologie clinique et biologique.
[17] D. English,et al. Iron-overload-related disease in HFE hereditary hemochromatosis. , 2008, The New England journal of medicine.
[18] D. Girelli,et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. , 2007, Blood.
[19] G. Koek,et al. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study. , 2007, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[20] L. Régent. [Management of hemochromatosis]. , 2007, Soins; la revue de reference infirmiere.
[21] J. Powell,et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis , 2007, Gut.
[22] J. Barton. Chelation therapy for iron overload , 2007, Nutrition reviews.
[23] Y. Kohgo,et al. Hepcidin is down-regulated in alcohol loading. , 2007, Alcoholism, clinical and experimental research.
[24] J. Barton,et al. Iron overload and prolonged ingestion of iron supplements: Clinical features and mutation analysis of hemochromatosis‐associated genes in four cases , 2006, American journal of hematology.
[25] A. Tavill,et al. A diagnostic approach to hemochromatosis. , 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[26] P. Brissot,et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases , 2006, Hepatology.
[27] D. Hewett,et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. , 2006, Archives of internal medicine.
[28] D. Greenwood,et al. HFE Genotype Modifies the Influence of Heme Iron Intake on Iron Status , 2005, Epidemiology.
[29] W. Sly,et al. Pathophysiology of hereditary hemochromatosis. , 2005, Seminars in liver disease.
[30] D. Greenwood,et al. Diet and genetic factors associated with iron status in middle-aged women. , 2005, The American journal of clinical nutrition.
[31] M. Pouchard,et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. , 2005, Blood.
[32] N. Andrews,et al. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. , 2005, The Journal of clinical investigation.
[33] E. Thomson,et al. Hemochromatosis and iron-overload screening in a racially diverse population. , 2005, The New England journal of medicine.
[34] B. Newman. Hemochromatosis blood donor programs: marginal for the red blood cell supply but potentially good for patient care , 2004, Transfusion.
[35] T. Power,et al. Hemochromatosis patients as voluntary blood donors. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[36] B. Nordestgaard,et al. Hemochromatosis mutations in the general population: iron overload progression rate. , 2004, Blood.
[37] P. Buggisch,et al. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases , 2003, British journal of haematology.
[38] J. Barton,et al. Phlebotomy-Mobilized Iron as a Surrogate for Liver Iron Content in Hemochromatosis Patients , 2003, Hematology.
[39] H. Klein,et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study , 2003, Transfusion.
[40] C. Yamashita,et al. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[41] V. Felitti,et al. Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. , 2002, Mayo Clinic proceedings.
[42] V. Felitti,et al. The C282Y mutation does not shorten life span. , 2002, Archives of internal medicine.
[43] M. Speechley,et al. Natural history of C282Y homozygotes for hemochromatosis. , 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[44] R. Hider. Nature of nontransferrin‐bound iron , 2002, European journal of clinical investigation.
[45] K. Hveem,et al. Persons with Screening-detected Haemochromatosis: as Healthy as the General Population? , 2002, Scandinavian journal of gastroenterology.
[46] F. Courtois,et al. [Genetic hemochromatosis and blood donation]. , 2001, Annales de medecine interne.
[47] K. Hveem,et al. Screening for Hemochromatosis: High Prevalence and Low Morbidity in an Unselected Population of 65,238 Persons , 2001, Scandinavian journal of gastroenterology.
[48] S. Glynn,et al. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis. , 2001, JAMA.
[49] T. Rouault,et al. MCV as a guide to phlebotomy therapyfor hemochromatosis , 2001, Transfusion.
[50] J. Barton,et al. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis , 2000, American journal of hematology.
[51] C. Seamark,et al. Should asymptomatic haemochromatosis be treated?Treatment can be onerous for patient and doctorCommentary: False certainty of clinical guidanceCommentary: Early treatment is essential , 2000, BMJ : British Medical Journal.
[52] C. Seamark,et al. Should asymptomatic haemochromatosis be treated?Treatment can be onerous for patient and doctorCommentary: False certainty of clinical guidanceCommentary: Early treatment is essential , 2000 .
[53] C. Bollard,et al. Blood donation by healthy individuals with haemochromatosis. , 2000, The New Zealand medical journal.
[54] J. Olynyk,et al. A population-based study of the clinical expression of the hemochromatosis gene. , 1999, The New England journal of medicine.
[55] A. Grindon,et al. Hemochromatosis probands as blood donors , 1999, Transfusion.
[56] R. Yip,et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. , 1999, The American journal of medicine.
[57] A. Grindon,et al. A survey of phlebotomy among persons with hemochromatosis , 1999, Transfusion.
[58] J. Cook,et al. Management of hemochromatosis. Hemochromatosis Management Working Group. , 1998, Annals of internal medicine.
[59] R. Gottschalk,et al. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis , 1998, Gut.
[60] P. Adams. Factors affecting the rate of iron mobilization during venesection therapy for genetic hemochromatosis , 1998, American journal of hematology.
[61] H. Schumacher. Arthropathy in hemochromatosis. , 1998, Hospital practice.
[62] B. Bacon,et al. Hepatic Iron Concentration in Hereditary Hemochromatosis Does Not Saturate or Accurately Predict Phlebotomy Requirements , 1998, American Journal of Gastroenterology.
[63] Å. Bruce,et al. The effect of withdrawal of food iron fortification in Sweden as studied with phlebotomy in subjects with genetic hemochromatosis , 1997, European Journal of Clinical Nutrition.
[64] Stephan Nussberger,et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter , 1997, Nature.
[65] D. Häussinger,et al. Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.
[66] W. Crosby,et al. Hereditary hemochromatosis. , 1993, Journal of the American Medical Association (JAMA).
[67] M. Pippard,et al. Iron Metabolism in Health and Disease , 1994 .
[68] C. Friedrich. Blood donation by patients with hemochromatosis. , 1993, JAMA.
[69] H. L. Penning. Blood donation by patients with hemochromatosis. , 1993, JAMA.
[70] P. Adams,et al. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy. , 1993, Journal of clinical gastroenterology.
[71] M. Worwood,et al. Serum ferritin, blood donation, iron stores and haemochromatosis , 1993, Transfusion medicine.
[72] W. Zoller,et al. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis. , 1992, Zeitschrift fur Gastroenterologie.
[73] M. Speechley,et al. Long-term survival analysis in hereditary hemochromatosis. , 1991, Gastroenterology.
[74] M. Nathanson,et al. Regulation of intestinal iron absorption and mucosal iron kinetics in hereditary hemochromatosis. , 1991, The Journal of laboratory and clinical medicine.
[75] N. N. Brown,et al. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. , 1990, Clinical chemistry.
[76] B. Bacon,et al. The pathology of hepatic iron overload: A free radical‐Mediated Process? , 1990, Hepatology.
[77] J. Cook,et al. Food iron absorption in idiopathic hemochromatosis. , 1989, Blood.
[78] D. Conte,et al. Effectiveness of Erythrocytapheresis in Idiopathic Hemochromatosis. Report of 14 Cases , 1989, The International journal of artificial organs.
[79] B. Bannwarth,et al. Haematological Adverse Effects of Histamine H2-Receptor Antagonists , 1988, Medical toxicology and adverse drug experience.
[80] O. Aruoma,et al. Nontransferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy. , 1988, Blood.
[81] K. S. Olsson,et al. The Effect of Iron Fortification of the Diet on Clinical Iron Overload in the General Population , 1988, Annals of the New York Academy of Sciences.
[82] M. Skolnick,et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. , 1988, The New England journal of medicine.
[83] W. Crosby. Hemochromatosis. Treatment to alleviate injury. , 1986, Archives of internal medicine.
[84] B. Halliwell,et al. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. , 1985, Clinical science.
[85] E. Henze,et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. , 1984, The American journal of cardiology.
[86] W. Bezwoda,et al. Effect of diet on the rate of iron accumulation in idiopathic haemochromatosis. , 1981, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[87] E. Rachmilewitz,et al. Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity , 1978, British journal of haematology.
[88] L. Powell. THE ROLE OF ALCOHOLISM IN HEPATIC IRON STORAGE DISEASE * , 1975, Annals of the New York Academy of Sciences.
[89] J. Cook,et al. Iron fortification of food: its measurement by the extrinsic tag method. , 1973, Blood.
[90] J. Stockman. Iron-Overload–Related Disease in HFE Hereditary Hemochromatosis , 2009 .
[91] E. Beutler,et al. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. , 2007, Alcoholism, clinical and experimental research.
[92] M. Cappellini,et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). , 2007, Blood.
[93] D. van der A,et al. HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[94] A. Piperno,et al. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. , 2005, Haematologica.
[95] P. Brissot,et al. Role of non-transferrin-bound iron in the pathogenesis of iron overload and toxicity. , 2002, Advances in experimental medicine and biology.
[96] P. Adams,et al. Eligibility and exclusion of hemochromatosis patients as voluntary blood donors. , 1998, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[97] W. Crosby. A history of phlebotomy therapy for hemochromatosis. , 1991, The American journal of the medical sciences.
[98] J. H. Jandl. Blood : textbook of hematology , 1987 .
[99] A. Walan,et al. Metabolic consequences of reduced gastric acidity. , 1985, Scandinavian journal of gastroenterology. Supplement.
[100] H. Koornhof,et al. Generalized infection with Yersinia enterocolitica and the role of iron. , 1979, Contributions to microbiology and immunology.
[101] W. Bezwoda,et al. Can iron fortification of flour cause damage to genetic susceptibles (idiopathic haemochromatosis and beta-thalassaemia major)? , 1978, Human genetics. Supplement.